/4575.T
4575.T Stock - CanBas Co., Ltd.
Healthcare|BiotechnologyJPX
$801.00-0.12%
$1.00 (-0.12%) • Dec 24
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.10
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $881.10
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for 4575.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$792.99 – $809.01
TARGET (TP)$921.15
STOP LOSS$736.92
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.30
52W High$1558.00
52W Low$739.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $108.94M |
| Gross Profit | $-820,000,000 | $-984,000,000 | $-671,000,000 | $-608,000,000 | $-322,000,000 |
| Gross Margin | N/A | N/A | N/A | N/A | -295.6% |
| Operating Income | $-1,109,000,000 | $-1,262,000,000 | $-965,965,000 | $-846,438,000 | $-547,000,000 |
| Net Income | $-1,157,000,000 | $-1,209,000,000 | $-1,244,108,000 | $-855,577,000 | $-531,034,000 |
| Net Margin | N/A | N/A | N/A | N/A | -487.4% |
| EPS | $-61.09 | $-67.87 | $-83.03 | $-88.31 | $-70.02 |
Company Overview
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
4575.TBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-17.70
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 11, 2025 | — | $-17.70 | — | — |
Q3 2025 | Aug 8, 2025 | — | $-16.87 | — | — |
Q2 2025 | May 13, 2025 | — | $-18.41 | — | — |
Q1 2025 | Feb 13, 2025 | — | $-9.63 | — | — |
Q4 2024 | Nov 13, 2024 | — | $-16.29 | — | — |
Q3 2024 | Aug 9, 2024 | — | $-36.39 | — | — |
Q2 2024 | May 10, 2024 | — | $-9.19 | — | — |
Q1 2024 | Feb 9, 2024 | — | $-11.18 | — | — |
Q4 2023 | Nov 10, 2023 | — | $-11.19 | — | — |
Q3 2023 | Aug 10, 2023 | — | $-33.22 | — | — |
Q2 2023 | May 12, 2023 | — | $-9.37 | — | — |
Q1 2023 | Feb 10, 2023 | — | $-15.84 | — | — |
Q4 2022 | Nov 11, 2022 | — | $-25.02 | — | — |
Q3 2022 | Aug 12, 2022 | — | $-22.08 | — | — |
Q2 2022 | May 13, 2022 | — | $-22.08 | — | — |
Q1 2022 | Feb 10, 2022 | — | $-22.08 | — | — |
Q4 2021 | Nov 11, 2021 | — | $-22.48 | — | — |
Q3 2021 | Aug 13, 2021 | — | $-17.51 | — | — |
Q2 2021 | May 14, 2021 | — | $-17.51 | — | — |
Q1 2021 | Feb 12, 2021 | — | $-17.51 | — | — |
Latest News
Loading news...
Frequently Asked Questions about 4575.T
What is 4575.T's current stock price?
CanBas Co., Ltd. (4575.T) is currently trading at $801.00 per share. The stock has moved -0.12% today.
What is the analyst price target for 4575.T?
No analyst price targets are currently available for this stock.
What sector is CanBas Co., Ltd. in?
CanBas Co., Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the JPX exchange.
What is 4575.T's market cap?
CanBas Co., Ltd. has a market capitalization of $15.78 billion, making it a large-cap company.
Does 4575.T pay dividends?
No, CanBas Co., Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare Sector3902.T
Medical Data Vision Co., Ltd.
$1686.00
Mkt Cap: $63.8B
4571.T
NANO MRNA Co.,Ltd.
$134.00
Mkt Cap: $9.5B
4579.T
RaQualia Pharma Inc.
$965.00
Mkt Cap: $23.6B
4588.T
Oncolys BioPharma Inc.
$903.00
Mkt Cap: $22.4B
4599.T
StemRIM
$259.00
Mkt Cap: $16.1B
4875.T
MediciNova, Inc.
$210.00
Mkt Cap: $10.3B
4978.T
ReproCELL Incorporated
$141.00
Mkt Cap: $13.4B
7774.T
Japan Tissue Engineering Co., Ltd.
$486.00
Mkt Cap: $19.7B
7776.T
CellSeed Inc.
$234.00
Mkt Cap: $8.1B
9229.T
Sunwels Co.,Ltd.
$350.00
Mkt Cap: $11.4B
Explore stocks similar to 4575.T for comparison